Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer
暂无分享,去创建一个
A. Haese* | G. Sauter | T. Schlomm | S. Steurer | T. Clauditz | R. Simon | S. Minner | M. Tsourlakis | H. Heinzer | M. Graefen | C. Fraune | H. Huland | D. Höflmayer | C. Hube-Magg | J. Izbicki | F. Büscheck | A. Luebke | E. Burandt | S. Weidemann | A. Heumann | B. Hager
[1] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[2] M. Pajic,et al. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. , 2018, Cancer research.
[3] N. Wu,et al. Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells , 2018, Drug design, development and therapy.
[4] C. A. Fraga,et al. ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells , 2017, Scientific Reports.
[5] J. Li,et al. Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer , 2017, Oncotarget.
[6] Dongmei Li,et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. , 2016, Biochemical and biophysical research communications.
[7] A. Haese*,et al. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. , 2016, European urology.
[8] B. Kerem,et al. Genomic Instability in Human Pluripotent Stem Cells Arises from Replicative Stress and Chromosome Condensation Defects. , 2016, Cell stem cell.
[9] Yeqing Huang,et al. Hsa‐miR‐146a‐5p modulates androgen‐independent prostate cancer cells apoptosis by targeting ROCK1 , 2015, The Prostate.
[10] Jian Li,et al. ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. , 2015, Anticancer research.
[11] Sijin Liu,et al. ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc , 2014, Oncogene.
[12] William L. Welbourn,et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer , 2014, International journal of urology : official journal of the Japanese Urological Association.
[13] G. B. Gelaleti,et al. Immunoexpression of ROCK-1 and MMP-9 as prognostic markers in breast cancer. , 2014, Acta histochemica.
[14] J. Samarut,et al. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2 , 2014, Oncogene.
[15] N. Anzai,et al. The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells , 2014, BMC Cancer.
[16] Lijun Lin,et al. Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma , 2014, International journal of molecular sciences.
[17] Chawnshang Chang,et al. Androgen receptor enhances entosis, a non‐apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells , 2013, The Prostate.
[18] S. Kurtz,et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.
[19] Y. Yang,et al. RhoA modulates functional and physical interaction between ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells , 2013, Cell Death and Disease.
[20] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[21] G. Sauter,et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.
[22] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[23] Sasidhar Vemula,et al. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment , 2013, Cell Death and Disease.
[24] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[25] Timothy J Wilt,et al. Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.
[26] P. Jones,et al. AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity , 2012, Clinical Cancer Research.
[27] Bruce J Trock,et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.
[28] Hyun-Man Kim,et al. The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. , 2012, Biomaterials.
[29] Kristopher Attwood,et al. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. , 2012, Molecular endocrinology.
[30] Tim Beißbarth,et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.
[31] Rvneet Singh,et al. Interobserver reproducibility of Gleason grading of prostatic adenocarcinoma among general pathologists. , 2011, Indian journal of cancer.
[32] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[33] Zhe Zhang,et al. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549 , 2011, Medical oncology.
[34] E. Jung,et al. Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.
[35] Yang Zhang,et al. Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro. , 2010, Canadian journal of physiology and pharmacology.
[36] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[37] Lin Deng,et al. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo , 2010, Cancer biology & therapy.
[38] Hartwig Huland,et al. Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.
[39] B. Leyland-Jones,et al. Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts , 2010, British Journal of Cancer.
[40] Sijin Liu,et al. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. , 2009, Cancer research.
[41] S. Mabuchi,et al. Fasudil Inhibits Lysophosphatidic Acid-Induced Invasiveness of Human Ovarian Cancer Cells , 2009, International Journal of Gynecologic Cancer.
[42] C. Cooper,et al. ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.
[43] Carol A Barnes,et al. Peripheral delivery of a ROCK inhibitor improves learning and working memory. , 2009, Behavioral neuroscience.
[44] K. Takakura,et al. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. , 2008, Neurologia medico-chirurgica.
[45] B. Alicke,et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models , 2006, Molecular Cancer Therapeutics.
[46] Baolin Zhang,et al. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. , 2006, Cancer research.
[47] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[48] S. Doggrell. Rho-kinase inhibitors show promise in pulmonary hypertension , 2005, Expert opinion on investigational drugs.
[49] Rong Zeng,et al. Regulation of PTEN by Rho small GTPases , 2005, Nature Cell Biology.
[50] Anne J. Ridley,et al. ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.
[51] H. Saya,et al. Roles of Rho-associated Kinase in Cytokinesis; Mutations in Rho-associated Kinase Phosphorylation Sites Impair Cytokinetic Segregation of Glial Filaments , 1998, The Journal of cell biology.
[52] Shuh Narumiya,et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.
[53] K. Nakao,et al. ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice , 1996, FEBS letters.
[54] H. Hidaka,et al. Mechanism of action of a novel antivasospasm drug, HA1077. , 1987, The Journal of pharmacology and experimental therapeutics.
[55] G. Sauter,et al. Quality aspects of TMA analysis. , 2010, Methods in molecular biology.
[56] Ronald Simon,et al. Tissue Microarrays , 2010, Methods in Molecular Biology.
[57] D. Alessi,et al. The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.